Clinical Trials
3 trialsNCT05475210 2024-03-13
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
Molecular Targeting Technologies, Inc.
Phase 1 Unknown
NCT03478358 2022-08-31
Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
Peking Union Medical College Hospital
Phase 1 Unknown
NCT03308682 2017-10-12
177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
Peking Union Medical College Hospital
Phase 1 Unknown